December 21, 2011 3:25 PM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Morgan Stanley has published a research report on Teva Pharmaceuticals (NASDAQ: TEVA) believing that 2012E guidance would have been higher had the Tricor battle not been lost.In the report, Morgan Stanley writes, "We and consensus expected Teva to launch generic Tricor in July 2012 under the terms of Teva's Dec. 09 settlement with Abbott. We now believe Teva will forfeit exclusivity as FDA will not approve Teva's genericformulation, per management. We believe TriCor would have added $0.15 in 2012, which in theory would have yielded a guidance midpoint of $5.73, 1% above cons' $5.67 (instead of midpoint of $5.58, 1.6% below cons)."Morgan Stanley maintains its Overweight rating and $47 price target on Teva, which is currently trading down $0.57 from yesterday's $42.34 closing price.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.